Hengrui Pharma Announces 2025 Final Dividend: RMB0.20 Per Share, HKD Payout Set for 27 May 2026

Bulletin Express04-17

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma) will distribute a 2025 final cash dividend of RMB2.00 per 10 shares (RMB0.20 per share), following shareholder approval on 16 April 2026.

The dividend will be paid in different currencies:

• A-share holders will receive RMB. • H-share holders will receive Hong Kong Dollars, converted at RMB0.87611 = HK$1.00, equating to HK$2.28 per 10 H shares (HK$0.23 per share, tax inclusive).

Key dates and administrative details are as follows:

• Record date: Monday, 11 May 2026. • Register closure (H shares): 4–11 May 2026; share transfer documents must be lodged by 16:30 on Thursday, 30 April 2026. • Payment date: Wednesday, 27 May 2026; dividend cheques will be mailed the same day.

Shares held in the company’s repurchase account or not yet cancelled by the record date are excluded from the payout. Should the total share capital change before the record date, the per-share distribution ratio will remain RMB0.20, with the aggregate amount adjusted accordingly.

Withholding tax rates on the dividend are:

• 10% for non-resident enterprise H-share holders (including HKSCC Nominees and other institutional nominees). • 10% for individual H-share holders, unless a lower treaty rate applies. • 20% for mainland individual investors holding H shares through Shanghai-Hong Kong or Shenzhen-Hong Kong Stock Connect; mainland enterprise investors under Southbound Trading must self-declare and pay relevant taxes. • 10% for Northbound Trading investors in A shares, with potential refunds available upon treaty approval.

Hengrui Pharma advises shareholders to consult professional tax advisers regarding specific PRC, Hong Kong, and cross-border tax implications.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment